Cencora Launches Cell and Gene Therapy Enablement for Health Systems

Analysts lifted their fair value estimate for Tecan Group from CHF 184.10 to CHF 195.73, reflecting updated price targets across recent research. Berenberg sits at the top of the range with a CHF 240 price target and a Buy rating, while Deutsche Bank raised its target in several steps from CHF 138 to CHF 151, then CHF 176, and most recently CHF 198, maintaining a Hold rating. Morgan Stanley moved its target from CHF 142 to CHF 160 and then to CHF 178 while keeping an Equal Weight stance, and Oddo BHF downgraded the stock to Neutral from Outperform with a CHF 192 target. The revised fair value reflects revenue growth assumptions of 5.53%, down from 5.56%, a net profit margin of 9.57% versus 9.70%, a future P/E of 27.00x versus 23.49x, and a discount rate of 4.90% versus 4.82%.

GRAIL announced in September 2026 that its Galleri multi-cancer early detection blood test showed strong performance in the PATHFINDER 2 study and received a favorable U.S. FDA advisory committee vote supporting its safety, benefit-risk profile and effectiveness for use alongside standard screening in adults aged 50 and older. The PATHFINDER 2 data indicated that adding Galleri increased cancers detected through screening more than six-fold with a very low false-positive rate, while the test also accurately pointed doctors to the likely cancer origin in over nine out of ten positive cases. The advisory committee's favorable vote and the PATHFINDER 2 results reinforce the core near-term catalyst around potential PMA approval and payer coverage, though GRAIL's high cash burn and lack of profitability remain the biggest risk. GRAIL's narrative projects $348.4 million revenue and $60.1 million earnings by 2029, with a $97.40 fair value implying a 32% downside to its current price, while some of the lowest estimate analysts were assuming only about US$277.6 million of revenue and a small US$49.4 million profit by 2029.